Literature DB >> 23238827

Levodopa improves motor deficits but can further disrupt cognition in a macaque Parkinson model.

Jay S Schneider1, Elsa Y Pioli, Yang Jianzhong, Qin Li, Erwan Bezard.   

Abstract

BACKGROUND: Levodopa effectively relieves motor symptoms in Parkinson's disease (PD), but has had inconsistent effects on cognition, even worsening some aspects of cognitive functioning. Therefore, remediation of PD cognitive deficits is a major unmet need. However, drug development efforts have been hampered by lack of an animal model in which motor and cognitive deficits can be examined simultaneously.
METHODS: Cynomolgus monkeys were trained to perform cognitive tasks and then chronically exposed to MPTP to slowly produce cognitive and motor deficits of parkinsonism.
RESULTS: Administration of L-dopa to these animals dose dependently improved motor functioning, but did not significantly improve cognitive performance. At doses that maximally improved motor function, additional cognitive deficits were observed. The present model of MPTP-induced parkinsonism recapitulates important motor and cognitive aspects of PD. Results with L-dopa mirror data derived from PD patients.
CONCLUSION: This model should allow more efficient testing of potential PD therapeutics to evaluate motor and cognitive functions simultaneously. © 2012 Movement Disorder Society.
Copyright © 2012 Movement Disorders Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23238827     DOI: 10.1002/mds.25258

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  9 in total

Review 1.  The neurobiological basis of cognitive impairment in Parkinson's disease.

Authors:  Glenda M Halliday; James B Leverenz; Jay S Schneider; Charles H Adler
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

2.  Pueraria mirifica extract and puerarin enhance proliferation and expression of alkaline phosphatase and type I collagen in primary baboon osteoblasts.

Authors:  Wacharaporn Tiyasatkulkovit; Suchinda Malaivijitnond; Narattaphol Charoenphandhu; Lorena M Havill; Allen L Ford; John L VandeBerg
Journal:  Phytomedicine       Date:  2014-08-28       Impact factor: 5.340

3.  Cerebrospinal fluid α-synuclein predicts cognitive decline in Parkinson disease progression in the DATATOP cohort.

Authors:  Tessandra Stewart; Changqin Liu; Carmen Ginghina; Kevin C Cain; Peggy Auinger; Brenna Cholerton; Min Shi; Jing Zhang
Journal:  Am J Pathol       Date:  2014-03-11       Impact factor: 4.307

4.  Amelioration of non-motor dysfunctions after transplantation of human dopamine neurons in a model of Parkinson's disease.

Authors:  M J Lelos; R J Morgan; C M Kelly; E M Torres; A E Rosser; S B Dunnett
Journal:  Exp Neurol       Date:  2016-02-04       Impact factor: 5.330

Review 5.  Toxin-Induced Experimental Models of Learning and Memory Impairment.

Authors:  Sandeep Vasant More; Hemant Kumar; Duk-Yeon Cho; Yo-Sep Yun; Dong-Kug Choi
Journal:  Int J Mol Sci       Date:  2016-09-01       Impact factor: 5.923

6.  Transplantation site influences the phenotypic differentiation of dopamine neurons in ventral mesencephalic grafts in Parkinsonian rats.

Authors:  Marija Fjodorova; Eduardo M Torres; Stephen B Dunnett
Journal:  Exp Neurol       Date:  2017-01-25       Impact factor: 5.330

Review 7.  Experimental Models of Cognitive Impairment for Use in Parkinson's Disease Research: The Distance Between Reality and Ideal.

Authors:  Yaohua Fan; Jiajun Han; Lijun Zhao; Chunxiao Wu; Peipei Wu; Zifeng Huang; Xiaoqian Hao; YiChun Ji; Dongfeng Chen; Meiling Zhu
Journal:  Front Aging Neurosci       Date:  2021-11-29       Impact factor: 5.750

8.  Development and Co-design of NeuroOrb: A Novel "Serious Gaming" System Targeting Cognitive Impairment in Parkinson's Disease.

Authors:  Bianca Guglietti; David A Hobbs; Bradley Wesson; Benjamin Ellul; Angus McNamara; Simon Drum; Lyndsey E Collins-Praino
Journal:  Front Aging Neurosci       Date:  2022-03-29       Impact factor: 5.750

9.  Cognitive dysfunction precedes the onset of motor symptoms in the MitoPark mouse model of Parkinson's disease.

Authors:  Xiuhua Li; Laney Redus; Cang Chen; Paul A Martinez; Randy Strong; Senlin Li; Jason C O'Connor
Journal:  PLoS One       Date:  2013-08-15       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.